Objective-Vascular cells, particularly endothelial cells, adopt aerobic glycolysis to generate energy to support cellular functions. The effect of endothelial glycolysis on angiogenesis remains unclear. 6-Phosphofructo-2-kinase/fructose-2, 6-bisphosphatase, isoform 3 (PFKFB3) is a critical enzyme for endothelial glycolysis. By blocking or deleting PFKFB3 in endothelial cells, we investigated the influence of endothelial glycolysis on angiogenesis both in vitro and in vivo. Approach and Results-Under hypoxic conditions or after treatment with angiogenic factors, endothelial PFKFB3 was upregulated both in vitro and in vivo. The knockdown or overexpression of PFKFB3 suppressed or accelerated endothelial proliferation and migration in vitro, respectively. Neonatal mice from a model of oxygen-induced retinopathy showed suppressed neovascular growth in the retina when endothelial PFKFB3 was genetically deleted or when the mice were treated with a PFKFB3 inhibitor. In addition, tumors implanted in mice deficient in endothelial PFKFB3 grew more slowly and were provided with less blood flow. A lower level of phosphorylated protein kinase B was observed in PFKFB3-knockdown endothelial cells, which was accompanied by a decrease in intracellular lactate. The addition of lactate to PFKFB3-knockdown cells rescued the suppression of endothelial proliferation and migration. Conclusions-The blockade or deletion of endothelial PFKFB3 decreases angiogenesis both in vitro and in vivo. Thus, PFKFB3 is a promising target for the reduction of endothelial glycolysis and its related pathological angiogenesis. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
A ngiogenesis is the growth of a new blood vessel from the existing vasculature. This capability is critical for many physiological and pathological processes. 1 When the angiogenic process is dysregulated, the formation of new blood vessels can take the form of pathological angiogenesis, leading to the development and progression of various malignant, ischemic, inflammatory, and immune diseases. 1, 2 Endothelial cells are especially critical in the process of angiogenesis. For example, the migration and proliferation of endothelial cells initiate the formation of capillary networks, which provide a frame for further vascular maturation. 3 Much attention has been given to investigating the effect of angiogenic growth factors on endothelial activities during angiogenesis. Indeed, several mechanisms have been described for the actions of these angiogenic factors, including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor among many others. 4 Endothelial cells have high glycolytic activity. [5] [6] [7] [8] [9] The level of glycolysis in endothelial cells is comparable with that of tumor cells and much higher than that of other healthy cells. 6 In addition, glycolytic flux in endothelial cells is >200-fold higher than glucose oxidation, fatty acid oxidation, and glutamine oxidation, resulting in the generation of >85% of the total cellular ATP content. 5 In glycolytic flux, the conversion of fructose-6-phosphate to fructose-1, 6-bisphosphate is 1 of 3 rate-limiting checkpoints. 6-Phosphofructo-1 kinase, the enzyme that catalyzes the above reaction, is activated by its allosteric activator, fructose-2, 6-bisphosphate. 10 In endothelial cells, fructose-2, 6-bisphosphate is synthesized by 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase, isoform 3 (PFKFB3). 11 A recent study demonstrated that PFKFB3driven glycolysis is important for the migration of endothelial cells. In response to angiogenic factors, PFKFB3-knockdown endothelial cells exhibit defects in the formation of filopodia and lamellipodia. 6 However, it remains unclear whether PFKFB3 is important for angiogenesis.
We were interested in determining whether the inhibition of PFKFB3 could suppress angiogenesis, especially pathological angiogenesis. Using PFKFB3 knockdown, overexpression, or inhibition of PFKFB3 activity with an inhibitor, we examined endothelial cell proliferation and tube formation in vitro. Furthermore, we generated floxed PFKFB3 (PFKFB3 fl/fl ) mice. By breeding these mice with endothelial cell-specific Cre (cdh5-Cre) mice, we generated mice with a deficiency of PFKFB3 specifically in endothelial cells. With these mice and their controls, the role of endothelial PFKFB3 in angiogenesis was evaluated by comparing the size of implanted tumors and the blood supply of these tumors and the severity of retinal neovascularization in the retina of mice from an oxygen-induced retinopathy model. Furthermore, the underlying mechanisms contributing to PFKFB3-associated angiogenesis were explored.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Hypoxia and Angiogenic Factors Upregulate Endothelial PFKFB3
To examine the effect of hypoxia on the expression of PFKFB, human umbilical vein endothelial cells (HUVECs) were cultured in an incubator with 0.5% oxygen for 24 hours. The mRNA expression levels of PFKFB isoforms 1 to 4 were analyzed with real-time reverse transcription-polymerase chain reaction. PFKFB isoforms 1 and 3 were increased by 1-and 5-fold, respectively, whereas isoforms 2 and 4 did not show significant changes compared with normoxia controls ( Figure 1A ). The upregulation of PFKFB3 protein expression in endothelial cells under hypoxic conditions was confirmed using Western blotting ( Figure 1C ). The expression of endothelial PFKFB3 in response to VEGF treatment was also examined. PFKFB3 mRNA expression was increased at 12 but not 24 hours after VEGF stimulation, and the protein expression was increased at both time points ( Figure 1B and 1D), indicating that in addition to the regulation of PFKFB3 at the transcriptional level, VEGF may also regulate endothelial PFKFB3 at the post-transcriptional level.
Endothelial PFKFB3 Is Involved in Endothelial Proliferation and Endothelial Tube Formation In Vitro
To examine whether PFKFB3 affects endothelial proliferation, endothelial cells pretreated with control adenovirus (Ad-shctl) or PFKFB3-knockdown adenovirus (Ad-shpfkfb3) were placed in endothelial growth cell medium under normoxic (21% oxygen, Figure 2A , left) or hypoxic (0.5% oxygen, Figure 2A , middle) conditions. Infection with PFKFB3-knockdown adenovirus resulted in a decreased expression of PFKFB3 in HUVECs ( Figure IA in the online-only Data Supplement) The growth of PFKFB3-knockdown endothelial cells decreased by 50% to 80% compared with control cells during a period of 96 hours (Figure 2A ). In contrast, the growth of endothelial cells infected with a PFKFB3-overexpressing adenovirus increased by 35% compared with endothelial cells treated with a control virus (Figure 2A , right). Furthermore, under normoxic conditions, the cell cycle was analyzed and bromodeoxyuridine (BrdU) incorporation was evaluated in endothelial cells cultured in a complete growth medium for 24 hours after the cells were synchronized by total fetal bovine serum depletion. Flow cytometry showed that the percentage of cells in S phase was 20% to 22% in control HUVECs, whereas this percentage decreased by 9% to 11% for PFKFB3-knockdown HUVECs ( Figure 2B ). Immunostaining in the BrdU incorporation assay showed that the percentage of BrdU-positive cells decreased by 30% to 35% in PFKFB3-knockdown cells and increased by 85% to 95% in PFKFB3-overexpressing cells compared with control cells ( Figure 2C ). To investigate whether PFKFB3 affected endothelial migration, a tube formation assay was conducted, which consisted of placing cells on growth factor-deprived Matrigel. The number of formed tubes was decreased by 40% to 46% in PFKFB3-knockdown HUVECs compared with control HUVECs ( Figure 2D ). In PFKFB3-overexpressing HUVECs, the number of tubes was 52% to 60% higher than that of control HUVECs ( Figure 2D ), indicating that PFKFB3 increases endothelial migration.
Endothelial PFKFB3 Participates in Pathological Angiogenesis In Vivo
To investigate the role of endothelial PFKFB3 in angiogenesis in vivo, floxed PFKFB3 mice (PFKFB3 WT ) were generated ( Figure 3A -3C) and then bred with cdh5-Cre mice to create mice with deficiency in PFKFB3 in endothelial cells only (PFKFB3 VEC-KO , Figure 3D ), and then both the oxygen-induced retinopathy (OIR) model and the tumor implantation model were used in these mice. For mouse pups in normal room air, the expression of retinal PFKFB3 in 7-day-old (P7), P12, and P17 mice was comparable (data not shown). In contrast, in OIR mice, the mRNA expression level of retinal PFKFB3 was decreased by 25% to 30% at P12 and increased by >2-fold at P17 compared with the expression level at P7 ( Figure 4A ). This dynamic change in retinal PFKFB3 expression was also observed at the protein level ( Figure 4B ). Retinal angiogenesis was evaluated by measuring the vascular area in retinal whole mounts after isolectin staining. The retinal density was slightly lower in PFKFB3 VEC-KO mice than in PFKFB3 WT mice at P4, and this difference was insignificant at P7 ( Figure IIA and IIB in the online-only Data Supplement). After P7, mice were exposed to 75% oxygen for 5 days. PFKFB3 VEC-KO mice at P12 showed an increase in avascular retinal area compared with PFKFB3 WT mice, although this increase was not statistically significant ( Figure 4C ). At P17, when the neovascular tuft reaches its maximum, the neovascular tuft area of PFKFB3 VEC-KO mice was 50% to 55% smaller than that of PFKFB3 WT mice ( Figure 4D ). Similar decreases in neovascular tuft area were also observed in control mouse pups treated with the PFKFB3 inhibitor 3PO (3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one) 12 ( Figure 4E ). In addition, the same OIR models were generated in heterozygotes of PFKFB3 deletion mice, [13] [14] [15] the retinal areas of both avascular and neovascular tuft were the same as those in littermate controls ( Figure III in the online-only Data Supplement), indicating that the deleting 1 allele of PFKFB3 gene in endothelial cells is not sufficient to alter endothelial angiogenesis.
Tumor implantation models were also used to examine the effect of endothelial PFKFB3 on angiogenesis. Adult female PFKFB3 VEC-KO and PFKFB3 WT mice were injected with B16 mouse melanoma under the back skin of the mouse. After tumor implantation, the tumor size and weight increased during a period of 18 days. However, at the same time were expanded for further analysis. Clone C10 was confirmed for homologous recombination with a single neo integration using the 5′, 3′ Neo probes. C, Heterozygous (F/+, PFKFB3 floxed) mice were obtained by breeding the male chimera with wild-type (WT; +/+) C57BL/6 females. D, Floxed mice were bred with cdh5-Cre mice to generate mice with a deficiency of PFKFB3 in the endothelial cells. Aortic endothelial cells were isolated from the mice and assayed for the expression of PFKFB3 with Western blotting.
points, the tumors in PFKFB3 VEC-KO were much smaller and lighter compared with those in PFKFB3 WT (Figure 4F and 4G). More importantly, the laser speckle contrast imaging showed 55% decreased blood flow in PFKFB3 VEC-KO mice as compared with their wild-type littermates, PFKFB3 WT mice ( Figure 4H ).
Protein Kinase B Acts Downstream of PFKFB3 in Endothelial Cells
Protein kinase B (AKT) and its phosphorylation are directly associated with angiogenesis. 16, 17 To examine whether AKT and phosphorylated AKT (pAKT) are involved in the effect of PFKFB3 on angiogenesis, the expression levels of AKT and pAKT in PFKFB3-knockdown HUVECs and control cells were examined using Western blotting. There were no significant differences in the AKT expression levels between PFKFB3-knockdown HUVECs and control cells. However, the pAKT expression level in PFKFB3-knockdown cells was decreased compared with control cells under both normoxic and hypoxic conditions ( Figure 5A ) and in response to human VEGF treatment ( Figure  IV in the online-only Data Supplement). Consistent with the in vitro results from cultured HUVECs, the expression level of retinal pAKT was decreased by 50% to 60% in OIR PFKFB3 VEC-KO mice compared with OIR PFKFB3 WT mice at P17 ( Figure 5B) . To further examine the correlation between the expression levels of pAKT and PFKFB3, HUVECs were treated with an adenovirus encoding PFKFB3 (Ad-PFKFB3). Treatment of HUVECs with Ad-PFKFB3 resulted in overexpression of PFKFB3 ( Figure IB in the online-only Data Supplement) and increased expression of pAKT in HUVECs ( Figure 5C ), suggesting that the expression level of PFKFB3 stimulates pAKT expression in endothelial cells. To determine the effect of decreased pAKT on endothelial proliferation and migration in PFKFB3 knockdown, PFKFB3-knockdown HUVECs were treated with an AKT activator to elevate the level of pAKT. During a period of 72 hours, control HUVECs cultured in complete growth cell medium with or without the addition of the AKT activator II exhibited similar levels of proliferation. However, the addition of the AKT activator II increased the proliferation of PFKFB3-knockdown HUVECs to levels similar to those observed in control HUVECs grown in a complete growth cell medium with or without the addition of the AKT activator II ( Figure 5D ). Compared with control HUVECs, PFKFB3-knockdown HUVECs exhibited a defect in tube formation. However, the addition of the AKT activator II improved tube formation in both control and PFKFB3-knockdown HUVECs ( Figure 5E ), resulting in no differences in tube formation between control and PFKFB3knockdown HUVECs. These results indicate that a decrease in pAKT in PFKFB3-knockdown HUVECs is a major cause of the observed defects in angiogenesis ( Figure 5E ).
Lactate Is Involved in PFKFB3-Mediated Endothelial Proliferation and Tube Formation
Recent studies have indicated the involvement of lactate in angiogenesis. To examine whether lactate plays a role in PFKFB-associated endothelial proliferation and migration, the levels of lactate were measured. Consistent with the differences observed in the expression level of pAKT in PFKFB3-knockdown, PFKFB3-overexpressing, and control HUVECs ( Figure 5A and 5C ), the levels of intracellular lactate and lactate in the cell medium were decreased in PFKFB3-knockdown cells and increased in PFKFB3overexpressing cells compared with their respective levels in control cells under both normoxic ( Figure 6A To determine the relationship between the expression level of pAKT and lactate, lactate was added to the cell medium. The levels of pAKT in PFKFB3-knockdown HUVECs cultured in a complete growth cell media were increased to levels similar to those in control HUVECs with the addition of lactate ( Figure 6B ). In addition, Ad-shpfkfb3-transduced endothelial cells were pretreated with lactate and then exposed to hypoxic conditions. The responses of pAKT to hypoxia after correcting the basal pAKT by lactate were dramatically inhibited in PFKFB3-knockdown cells compared with control cells ( Figure VI in the online-only Data Supplement). The addition of lactate to the complete growth cell medium in which control HUVECs were cultured did not significantly enhance the expression of pAKT ( Figure 6B) . Similarly, during a period of 72 hours, the culture of control HUVECs in complete growth cell medium with the addition of lactate did not alter proliferation. In contrast, the culture of PFKFB3-knockdown HUVECs in complete growth cell medium with the addition of lactate increased the proliferation to levels similar to that of control HUVECs grown in a complete growth cell medium with or without the addition of lactate ( Figure 6C ). As shown in Figures 2D and 5E , compared with control HUVECs, PFKFB3-knockdown HUVECs exhibited a defect in tube formation. The addition of lactate to the medium improved tube formation in both PFKFB3-knockdown HUVECs and control cells ( Figure 6D ). Furthermore, the addition of lactate to PFKFB3-knockdown HUVECs rescued the observed decrease in tube formation, indicating that a decrease in lactate in PFKFB3-knockdown HUVECs is a major cause of the defects in tube formation observed in this group of cells.
Discussion
Angiogenic factors upregulate endothelial PFKFB3. Endothelial cells are highly glycolytic even under resting conditions. 6,9 A recent study indicated that the glycolysis level in endothelial cells is much higher than in any other healthy cells, including cardiomyocytes, hepatocytes, fibroblasts, and macrophages, and is even similar to that of many tumor cells. The majority of intracellular ATP is generated from glycolysis in cultured endothelial cells. PFKFB3 is critical in endothelial cell glycolysis. The knockdown of PFKFB3 protein expression in endothelial cells (76%-84%) results in a decrease in glycolysis (35%-40%), indicating that PFKFB3 plays a significant role in the physiological activity of endothelial cells. PFKFB3 is also critical for glycolysis under pathological conditions. A recent study demonstrated that after VEGF stimulation, PFKFB3 protein expression was significantly upregulated. 6 We have studied the expression of all of the isoforms of PFKFB and found that the PFKFB3 isoform is the most significantly upregulated in stimulated endothelial cells. This upregulation was also observed in vivo, as evidenced by OIR retinal PFKFB3 expression. Compared with the other isoforms of PFKFB, PFKFB encoded by PFKFB3 is an enzyme with a kinase activity >700-fold higher than its phosphatase activity, thereafter signaling to achieve a high level of glycolysis in proliferative endothelial cells.
Endothelial PFKFB3 participates in pathological angiogenesis. In cancers of the breast, colon, lung, pancreas, prostate, and ovary, PFKFB3 exhibited increased protein and mRNA expression as well as increases of its phosphorylated form compared with healthy controls. 10, 11, 18 This increased expression leads to high rates of aerobic glycolysis in tumor cells, a phenomenon known as the Warburg effect. 19 In addition to general tumor cells, vascular cells in tumors also exhibit an increased expression and activation of PFKFB3, suggesting that endothelial PFKFB3 is involved in the Warburg effect. 11, 20 In our study, the tumor blood supply and tumor size were decreased in mice deficient in endothelial PFKFB3 compared with control mice, demonstrating that PFKFB3 in endothelial cells is indeed critical for tumor angiogenesis. The role of endothelial PFKFB3 in pathological angiogenesis was further supported by its effect on neovascularization in OIR mouse retinas. In this model, both the selective deletion of endothelial PFKFB3 and the application of a PFKFB3 inhibitor to mice dramatically suppressed retinal neovascularization. In addition, consistent with the data from De Bock et al, 6 we found that the density of retinal vessels in newborn mouse pups deficient in endothelial PFKFB3 was lower than that in control pups ( Figure IIA in the online-only Data Supplement). Furthermore, in OIR mice, the vascular regrowth in the avascular area of the retina was also relatively delayed in mice deficient in endothelial PFKFB3 compared with control mice, implying that endothelial PFKFB3 may play a role in physiological angiogenesis.
The underlying mechanisms for the role of endothelial PFKFB3 in pathological angiogenesis arise from the influence of this gene (enzyme) in endothelial migration and proliferation. PFKFB3 affects endothelial migration by regulating the formation of filopodia and lamellipodia and directional migration. One possible mechanism underlying this effect is that PFKFB3 compartmentalizes with F-actin in motile protrusions to provide ATP. 6 Thus, deficiency in or knockdown of PFKFB3 impairs tip cell formation. Consistent with these results, we also observed a significant defect in the formation of lamellipodia in PFKFB3-knockdown endothelial cells under both normoxic and hypoxic conditions ( Figure VII in the online-only Data Supplement). In addition, an analysis of the endothelial cell tube formation indicated that endothelial tubes are formed much more rapidly in control endothelial cells than in PFKFB3-knockdown cells. The tube formation assay was performed within 6 to 8 hours after the endothelial cells were placed on the Matrigel, indicating that the compromised tube formation is mainly attributable to a defect in migration. PFKFB3 is also important for endothelial proliferation. [21] [22] [23] In both HeLa cells and lymphocytes, a temporal expression pattern of PFKFB3 has been observed during the cell cycle progression. PFKFB3 appears in mid-to-late G1 and is vital for cell division. 22 Silencing PFKFB3 dramatically reduced T-lymphocyte proliferation. 21 Consistent with these findings, in the current study, the knockdown of endothelial PFKFB3 prevented endothelial cells from proceeding to the S phase, resulting in a much lower proliferative rate compared with control endothelial cells under both normoxic and hypoxic conditions ( Figure 2B and Figure VIII in the online-only Data Supplement). In addition, we have found that under hypoxic condition, knockdown of PFKFB3 accelerated endothelial apoptosis, indicating that, in addition to endothelial proliferation and migration, a PFKFB3-knockdown-associated decrease in angiogenesis may involve other mechanisms ( Figure IX in the online-only Data Supplement).
Lactate-induced AKT phosphorylation is involved in PFKFB3driven endothelial angiogenesis. De Bock et al 6 examined PFKFB3-knockdown cells and found no significant differences in ATP levels, cell death, oxidative stress, glucose oxidation, and fatty acid oxidation or respiration between these cells and wild-type controls. Therefore, because of the cellular adaptation to PFKFB3 silencing, cellular energy distress does not arise, and thus, energy distress is not responsible for the compromised angiogenesis observed in PFKFB3-knockdown endothelial cells. Because of a high glycolytic activity, activated endothelial cells produce a substantial amount of lactate. In endothelial cells, lactate functions as a signaling molecule for angiogenesis. [24] [25] [26] [27] [28] [29] Lactate acts through AxI, Tie2, and VEGF receptor 2 to activate PI3K (phosphoinositide 3-kinase)/AKT. 28 Likely, Pim-1 and foxo transcription factors are also involved in the lactate-mediated effect because it has been demonstrated that these molecules are tied to AKT in mediating proliferation and antiapoptotic action of glycolysis. 30, 31 The effect of lactate on angiogenesis has been demonstrated in a few models, including pulmonary microvascular endothelial cell proliferation and the healing of superficial and ischemic wounds. The knockdown or overexpression of PFKFB3 in endothelial cells decreased or increased the levels of lactate, respectively, whereas the latter closely correlated with the levels of pAKT. The addition of lactate to PFKFB3-knockdown endothelial cells increased pAKT levels and rescued impaired endothelial migration. Thus, as summarized in Figure 6E , endothelial PFKFB3 knockdown led to a low level of glycolysis and a low level of intracellular lactate and secreted lactate, which caused a decrease in pAKT and a failure to signal properly for the generation of a strong angiogenic response. In addition, low levels of lactate and glycolysis in PFKFB3knockdown endothelial cells are not able to provide sufficient substrates for the generation of macromolecules, including DNA, RNA, and relevant lipids, which lead to the impairment of endothelial proliferation 19, 20 (Figure 6E) .
As a key enzyme of the pentose phosphate pathway, glucose-6-phosphate dehydrogenase (G6PD) critically regulates glucose metabolism during angiogenesis and tissue repair. 32, 33 Deficiency of G6PD decreases endothelial proliferation, migration, and tube formation, whereas activation or overexpression of G6PD increases angiogenesis as well as cardiac repair in diabetes mellitus. The effect of G6PD on angiogenesis and tissue repair involves Flk-1, AKT, and Pim-1. 32, 33 However, pentose phosphate pathway was increased during PFKFB3 knockdown. 34 Given this, PFKFB3 seems to not act through G6PD-associated pathway to alter endothelial angiogenesis, although PFKFB3 knockdown and G6PD deficiency share many similarities in the effect and mechanisms.
This study has indicated that the knockdown or inhibition of PFKFB3 leads to significant suppression of pathological angiogenesis. In addition to tumors/cancers, many other diseases are also associated with pathological angiogenesis. For instance, retina angiogenesis is an important cause for vision loss in retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration. 35 Also, angiogenesis in atherosclerotic lesion is an important contributor to the formation and the progression of atherosclerosis, whereas some antiangiogenic approaches suppress atherosclerosis. 36 Thus, PFKFB3 is a promising target for the treatment of pathological angiogenesis and its associated diseases.
The glycolytic activity of endothelial cells is critical for angiogenesis. Fructose-2, 6-bisphosphate, a product of 6-phosphofructo-2-kinase/ fructose-2, 6-bisphosphatase, isoform 3 (PFKFB3), is an activator of 6-phosphofructo-1 kinase, 1 rate-limiting checkpoint of glycolysis. Using both chemical and genetic approaches, we demonstrated that the knockdown or inhibition of endothelial PFKFB3 reduced endothelial glycolysis, leading to significant suppression of endothelial proliferation in vitro and pathological angiogenesis in vivo in murine models of tumor growth and oxygen-induced retinopathy. Furthermore, we found that lactate-associated Akt phosphorylation contributed to PFKFB3-modulated angiogenesis. Many diseases are associated with pathological angiogenesis, including tumors/cancers, retinopathies (retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration), and the formation and the progression of atherosclerosis. This study indicates that PFKFB3 is a promising target for the treatment of pathological angiogenesis and its associated diseases.
Significance
